Indian drug developer Hetero said Monday it has received emergency use approval from the country’s health authorities to create a generic version of Roche Holding AG’s COVID-19 drug.
Hetero expects to make the treatment, tocilizumab, available in India under the brand name Tocira by the end of the month. Tocilizumab faces a global shortage as the highly contagious COVID-19 Delta variant leads to more cases in several countries.
The number of COVID-19 cases in India has fallen from levels reached during the second wave in April and May, although health experts believe the country should prepare for a third wave in October.
Roche’s blockbuster arthritis drug, tocilizumab, reduces the risk of death in patients hospitalized with severe COVID-19, along with shortening recovery time and reducing the need for mechanical ventilation.
Tocira will be made by Hetero’s unit at the Hyderabad plant.
Hetero, which makes COVID-19 treatments such as remdesivir and favipiravir, also had filed for emergency approval in July for Merck’s COVID-19 drug molnupiravir.
(This story was not edited by NewsMadura staff and was generated automatically from a syndicated feed.)